Ayahuasca research in the US: meeting FDA and DEA regulations



Leanna Standish ND, PhD, MSAOM, L.Acup, FABNO

AIMS Institute

University of Washington School of Medicine Department of Radiology

Bastyr University

Seattle Washington


June 2019

2019 WORLD AYAHUASCA CONFERENCE

Istandish@aimsinstitute.net

How shall we proceed with impeccable scientific research of the sacred while respecting and honoring the indigenous healers in South

America?



My first ayahuasca experience in 1999 in Brazil

A direct experience of transcendence and the healing power of

ayahuasca

Astonished awakening....







Luis Eduardo Luna PhD








How to bring the beauty and power of ayahuasca into a research environment while honoring and respecting the ancient wisdom and tradition.






GOAL since 1999


To manufacture potent, standardized, stable ayahuasca tea suitable for a Phase I trial approved by the US Food & Drug Administration (FDA) and meets US Drug Enforcement Agency (DEA) security requirements

Make ayahuasca healing available to everyone who needs it.

12 critical steps towards the first clinical trial of ayahuasca in the United States




Learn and study all things Ayahuasca....



Kat Harrison




Eduardo Luna



Ali Maya

Wayra

Collect ayahuasca tea samples from ceremonies conducted in Brazil, Peru and North America




DMT concentrations ranged from 0.28 – 0.78 mg/ml in concentration. There were no significant differences between the mean DMT concentration between teas made in South America (0.49 mg/ml + 0.17) and those made in Hawaii (0.48 + 0.14 mg/ml).

Learn and do chemistry

Active alkaloid constituent	Callaway 1996 UDV church Ayahuasca tea single sample (mg/ml ± SD)	Mean <u>+</u> SD of 15 ayahuasca tea samples made in S. America or Hawaii(mg/ml <u>+</u> SD)
DMT	0.24	0.49 <u>+</u> 0.14
Harmine	1.70	2.26 <u>+</u> 0.83
THH	1.07	1.64 <u>+</u> 0.52
Harmaline	0.20	0.21 <u>+</u> 0.09


STEP 2
Protect, grow and study
B. caapi and P. viridis

FDA Good Agricultural Practices













Vouchered by herbaria in Iquitos, British Columbia and Missouri Botanical Gardens







Teach and learn from graduate students



NIH T32 grant and Heffter Foundation grant for bench work at Bastyr University



Dr. Dawn Reardon



Rebecca Mains

Trevor Clark

Hayley Prescott

Leanna Standish




Make experimental batches of ayahuasca tea in a quantitative STEP 3 controlled laboratory setting with DEA oversight















Obtain FDA approval for a Phase I trial for a specific formulation of ayahuasca tea using specific vouchered *B. caapi* and *P. viridis* cultivars

Safety and dose finding study N = 12




Freddie Ann Hoffman MD Heterogeneity LLC



Contract with a botanical manufacturing site in the US that meets FDA GMP regulations and could be modified to meet DEA security requirements (Heron Botanicals in Kingston Washington)









Create a clinic where our ayahuasca trials can safely be conducted under IRB oversight with AIMS clinical staff who have been trained by MAPS (AIMS Institute in Seattle).





Nathan Schmidt ARNP Sunil Aggarwal MD, PhD



Angela Ward RN










AIMS Institute in Seattle







First 6 steps accomplished. It only took 20 years.

- 1. Growing and harvesting the sacred plants in the U.S. that meet Good Agricultural Practices (Hawaii)
- 2. Learning from ayahuascaros how to make a potent ayahuasca tea (Brazil, Peru, Hawaii)
- 3. Making experimental batches of ayahuasca tea in a quantitative controlled laboratory setting with DEA oversight
- 4. Obtaining FDA approval for a Phase I trial for a specific formulation of ayahuasca tea using specific vouchered *B. caapi* and *P. viridis* cultivars (Standish Medicine in Seattle)
- 5. Contracting with a botanical manufacturing site in the US that meets FDA GMP regulations and could be modified to meet DEA security requirements (Heron Botanicals in Kingston Washington)
- 6. Creating a clinic where our ayahuasca trials can safely be conducted under IRB approval with AIMS clinical staff who have been trained by MAPS (AIMS Institute in Seattle).

STEPS 7-12 are next...

- 7. Obtain DEA manufacturing license application, which entails modifications to the botanical drug manufacturing and laboratory site and a DEA inspection
- 8. Conduct R&D small-scale to large-scale production of our standardized botanical drug (Heron Botanicals)
- 9. Contract with FDA and DEA approved outsourced labs for pre-clinical toxicology studies
- 10. Submit the pre-clinical toxicology data to the FDA
- 11. Complete the Phase I safety and dose finding study to be conducted at AIMS Institute in Seattle
- 12. Publish the trial results and obtain FDA approval for the Phase II trials.

Victoria Hale, PhD Sunil Aggarwal, MD, PhD Eric Yarnell, ND







THE DREAM TEAM

\$50,000 grant from Seattle lawyer Robin Wechkin and Microsoft's Bill Bolosky to MAPS to support this work





We will need to raise millions of dollars to finish the Phase I trial.

Donate to MAPS to support this work!

https://tinyurl.com/ayascience

